Meny

Javascript is not activated in your browser. This website needs javascript activated to work properly.
Du är här

Bendamustine compared with chlorambucil in previously untreated patients with chronic lymphocytic leukaemia: updated results of a randomized phase III trial

Författare:
  • Wolfgang U. Knauf
  • Toshko Lissitchkov
  • Ali Aldaoud
  • Anna M. Liberati
  • Javier Loscertales
  • Raoul Herbrecht
  • Gunnar Juliusson
  • Gerhard Postner
  • Liana Gercheva
  • Stefan Goranov
  • Martin Becker
  • Hans-Joerg Fricke
  • Francoise Huguet
  • Ilaria Del Giudice
  • Peter Klein
  • Karlheinz Merkle
  • Marco Montillo
Publiceringsår: 2012
Språk: Engelska
Sidor: 67-77
Publikation/Tidskrift/Serie: British Journal of Haematology
Volym: 159
Nummer: 1
Dokumenttyp: Artikel
Förlag: Wiley-Blackwell Publishing

Sammanfattning

The efficacy of bendamustine versus chlorambucil in a phase III trial of previously untreated patients with Binet stage B/C chronic lymphocytic leukaemia (CLL) was re-evaluated after a median observation time of 54months in May 2010. Overall survival (OS) was analysed for the first time. At follow-up, investigator-assessed complete response (CR) rate (21.0% vs 10.8%), median progression-free survival (21.2 vs 8.8months; P<0.0001; hazard ratio 2.83) and time to next treatment (31.7 vs 10.1months; P<0.0001) were improved for bendamustine over chlorambucil. OS was not different between groups for all patients or those =65years, >65 years, responders and non-responders. However, patients with objective response or a CR experienced a significantly longer OS than non-responders or those without a CR. Significantly more patients on chlorambucil progressed to second/further lines of treatment compared with those on bendamustine (78.3% vs 63.6%; P=0.004). The benefits of bendamustine over chlorambucil were achieved without reducing quality of life. In conclusion, bendamustine is significantly more effective than chlorambucil in previously untreated CLL patients, with the achievement of a CR or objective response appearing to prolong OS. Bendamustine should be considered as a preferred first-line option over chlorambucil for CLL patients ineligible for fludarabine, cyclophosphamide and rituximab.

Disputation

Nyckelord

  • Medicine and Health Sciences
  • bendamustine
  • chlorambucil
  • chronic lymphocytic leukaemia
  • complete
  • response
  • overall survival

Övriga

Published
Yes
  • ISSN: 0007-1048

Box 117, 221 00 LUND
Telefon 046-222 00 00 (växel)
Telefax 046-222 47 20
lu [at] lu [dot] se

Fakturaadress: Box 188, 221 00 LUND
Organisationsnummer: 202100-3211
Om webbplatsen